Background: The introduction of ART had a momentous impact on women living with Human immunodeficiency virus (HIV) with cervical cancer positive. The incidence of AIDS-defining cancers has decreased, but the risk is still higher than general population. Women living with (HIV) have a high prevalence of human papilloma virus (HPV) infection and correlated disease, including cervical cancer. HIV-related risk factors, such as immunodeficiency and chronic persistence of infection play an important role in its pathogenesis. HPV vaccine, screening and early antiretroviral therapies, are recommended to reduce the risk of developing cervical cancer among the WLH. Methodology: In this review, we considered the studies published about cervical cancer in women living with HIV between 2019 to 2022 in Kenya. We comprised only recent articles written in English, identifying 50 records. We excluded 10 articles after reading title and abstract. At the end of the assessment we included in our review the 40 full-text articles. Results: The normal history of HIV infection has been intensely modified by the introduction of HAART, but HIV-infected women still have a higher risk of developing HPV-related diseases, including cervical cancer. Conclusion: Further studies are needed to obtain data about interactions between HAART and HPV-related lesions. Lastly, psychological support for cervical cancer survivors and management of late effects are needed.
| Published in | Cancer Research Journal (Volume 10, Issue 4) |
| DOI | 10.11648/j.crj.20221004.12 |
| Page(s) | 81-84 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Cervical Cancer, Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), Screening, Vaccination
| [1] | Parkin D, Ferlay J, Hamdi-Cherif M, (2006). Cervix Cancer. in: Cancer in Africa: Epidemiology and Prevention. Lyon: IARC Press; 268-76. |
| [2] | Pomerantz RJ, Nunnari G. HIV and GB virus C--can two viruses be better than one? N Engl J Med 2004; 350: 963-965. |
| [3] | Pinzone MR, Berretta M, Cacopardo B, Nunnari G. Epstein-barr virus- and Kaposi sarcoma-associated herpes virus-related malignancies in the setting of human immunodeficiency virus infection. Semin Oncol 2015; 42: 258-271. |
| [4] | Pinzone MR, Di Rosa M, Celesia BM, Condorelli F, Malaguarnera M, Madeddu G, Martellotta F, Castronuovo D, Gussio M, Coco C, Palermo F, Cosentino S, Cacopardo B, Nunnari G. LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals. Eur Rev Med Pharmacol Sci 2013; 17: 1938-1950. |
| [5] | Goncalves PH, Montezuma-Rusca JM, Yarchoan R, Uldrick TS. Cancer prevention in HIV-infected populations. Semin Oncol 2016; 43: 173-188. |
| [6] | Robbins HA, Strickler HD, Massad LS, Pierce CB, Darragh TM, Minkoff H, Keller MJ, Fischl M, Palefsky J, Flowers L, Rahangdale L, Milam J, Shrestha S, Colie C, D Souza G. Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach. AIDS 2017; 31: 1035-10. |
| [7] | Ceccarelli M, Condorelli F, Venanzi Rullo E, Pellicanò GF. Editorial - Improving access and adherence to screening tests for cancers: a new, though old, challenge in the HIV epidemics. World Cancer Res J 2018; 5: e1030. |
| [8] | Travassos AG, Netto E, Xavier-Souza E, Nóbrega I, Adami K, Timbó M, Abbehusen K, Fernandes S, Duran C, Haguihara T, Ferreira F, Brites C Predictors of HPV incidence and clearance in a cohort of Brazilian HIV-infected women. PLoS One 2017; 12: e0185423. |
| [9] | Heard I. Prevention of cervical cancer in women with HIV. Curr Opin HIV AIDS 2009; 4: 68-73. |
| [10] | Moodley M, Moodley J, Kleinschmidt I. Invasive cervical cancer and human immunodeficiency virus (HIV) infection: a South African perspective. Int J Gynecol Cancer 2001; 11: 194-197. |
| [11] | Ceccarelli M, Venanzi Rullo E, Facciolà A, Madeddu G, Cacopardo B, Taibi R, D’Aleo F, Pinzone MR, Picerno I, Di Rosa M, Visalli G, Condorelli F, Nunnari G, Pellicanò GF. Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HIV: a systematic review. Oncotarget 2018; 9: 17171-17180. |
| [12] | Visalli G, Currò M, Facciolà A, Riso R, Mondello P, Laganà P, Di Pietro A, Picerno I, Spataro P. Prevalence of human papillomavirus in saliva of women with HPV genital lesions. Infect Agents Cancer 2016; 11: 48. |
| [13] | Stanley MA, Sterling JC. Host responses to infection with human papillomavirus. Curr Probl Dermatol 2014; 45: 58-74. |
| [14] | McBride AA, Warburton A. The role of integration in oncogenic progression of HPV-associated cancers. PLoS Pathog 2017; 13: e1006211- e1006217. |
| [15] | Martellotta F, Fiorica F, Malorgio A, Stefanelli A. Anal cancer in HIV-positive patients: state of the art. World Cancer Res J 2016; 3: e736. |
| [16] | Mwaka AD, Orach CG, Were EM, Lyratzopoulos G, Wabinga H, Roland M. Awareness of cervical cancer risk factors and symptoms: cross-sectional community survey in post-conflict northern Uganda. Health Expect 2015; 19: 854-867. |
| [17] | D’Andrea F, Ceccarelli M, Venanzi Rullo E, Facciolà A, D’Aleo F, Cacopardo B, Iacobello C, Costa A, Altavilla G, Pellicanò GF, Nunnari G. Cancer screening in HIV-infected patients: early diagnosis in a high-risk population. World Cancer Res J 2018; 5: e1130. |
| [18] | Mejilla A, Li E, Sadowski CA. Human papilloma virus (HPV) vaccination: questions and answers. Can Pharm J 2017; 150: 306-315. |
| [19] | Kash N, Lee M, Kollipara R, Downing C, Guidry J, Tyring S. Safety and efficacy data on vaccines and immunization to human papillomavirus. J Clin Med 2015; 4: 614-633. |
| [20] | Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review. Expert Opin Drug Saf 2015; 14: 697-712. |
| [21] | FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927. |
| [22] | Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, Saah A, Aberg JA, Cu-Uvin S. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 2014; 59: 127-135. |
| [23] | Società Italiana di Malattie Infettive e Tropicali (2017) Linee Guida Italiane sull’utilizzo della Terapia Antiretrovirale e la gestione diagnostico-clinica delle persone con infezione da HIV-1. Accessed 15 October 2018 http://www.salute.gov.it/imgs/C_17_pubblicazioni_2696_allegato.pdf |
| [24] | Lorincz A, Castanon A, Lim AWW, Sasieni P. New strategies for human papillomavirus-based cervical screening. Womens Health (Lond) 2013; 9: 443-452. |
| [25] | Karsa von L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, Törnberg S, Anttila A. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res 2015; 1: 22-31. |
| [26] | Bourgioti C, Chatoupis K, Moulopoulos LA. Current imaging strategies for the evaluation of uterine cervical cancer. World J Radiol 2016; 8: 342-414. |
| [27] | Minkoff H, Zhong Y, Burk RD, Palefsky JM, Xue X, Watts DH, Levine AM, Wright RL, Colie C, D’Souza G, Massad LS, Strickler HD. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 2010; 201: 681-690. |
| [28] | Chuang LT, Temin S, Camacho R, Dueñas-Gonzalez A, Feldman S, Gultekin M, Gupta V, Horton S, Jacob G, Kidd EA, Lishimpi K, Nakisige C, Nam J-H, Ngan HYS, Small W, Thomas G, Berek JS. Management and care of women with invasive cervical cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. J Glob Oncol 2016; 2: 311-340. |
| [29] | Pfaendler KS, Wenzel L, Mechanic MB, Penner KR. cervical cancer survivorship: long-term quality of life and social support. Clin Ther 2015; 37: 39-48. |
APA Style
Silas Onyango Awuor, Eric Omori Omwenga. (2022). Cervical Cancer in Women Living with HIV: A Review of the Literature. Cancer Research Journal, 10(4), 81-84. https://doi.org/10.11648/j.crj.20221004.12
ACS Style
Silas Onyango Awuor; Eric Omori Omwenga. Cervical Cancer in Women Living with HIV: A Review of the Literature. Cancer Res. J. 2022, 10(4), 81-84. doi: 10.11648/j.crj.20221004.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.crj.20221004.12,
author = {Silas Onyango Awuor and Eric Omori Omwenga},
title = {Cervical Cancer in Women Living with HIV: A Review of the Literature},
journal = {Cancer Research Journal},
volume = {10},
number = {4},
pages = {81-84},
doi = {10.11648/j.crj.20221004.12},
url = {https://doi.org/10.11648/j.crj.20221004.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20221004.12},
abstract = {Background: The introduction of ART had a momentous impact on women living with Human immunodeficiency virus (HIV) with cervical cancer positive. The incidence of AIDS-defining cancers has decreased, but the risk is still higher than general population. Women living with (HIV) have a high prevalence of human papilloma virus (HPV) infection and correlated disease, including cervical cancer. HIV-related risk factors, such as immunodeficiency and chronic persistence of infection play an important role in its pathogenesis. HPV vaccine, screening and early antiretroviral therapies, are recommended to reduce the risk of developing cervical cancer among the WLH. Methodology: In this review, we considered the studies published about cervical cancer in women living with HIV between 2019 to 2022 in Kenya. We comprised only recent articles written in English, identifying 50 records. We excluded 10 articles after reading title and abstract. At the end of the assessment we included in our review the 40 full-text articles. Results: The normal history of HIV infection has been intensely modified by the introduction of HAART, but HIV-infected women still have a higher risk of developing HPV-related diseases, including cervical cancer. Conclusion: Further studies are needed to obtain data about interactions between HAART and HPV-related lesions. Lastly, psychological support for cervical cancer survivors and management of late effects are needed.},
year = {2022}
}
TY - JOUR T1 - Cervical Cancer in Women Living with HIV: A Review of the Literature AU - Silas Onyango Awuor AU - Eric Omori Omwenga Y1 - 2022/11/29 PY - 2022 N1 - https://doi.org/10.11648/j.crj.20221004.12 DO - 10.11648/j.crj.20221004.12 T2 - Cancer Research Journal JF - Cancer Research Journal JO - Cancer Research Journal SP - 81 EP - 84 PB - Science Publishing Group SN - 2330-8214 UR - https://doi.org/10.11648/j.crj.20221004.12 AB - Background: The introduction of ART had a momentous impact on women living with Human immunodeficiency virus (HIV) with cervical cancer positive. The incidence of AIDS-defining cancers has decreased, but the risk is still higher than general population. Women living with (HIV) have a high prevalence of human papilloma virus (HPV) infection and correlated disease, including cervical cancer. HIV-related risk factors, such as immunodeficiency and chronic persistence of infection play an important role in its pathogenesis. HPV vaccine, screening and early antiretroviral therapies, are recommended to reduce the risk of developing cervical cancer among the WLH. Methodology: In this review, we considered the studies published about cervical cancer in women living with HIV between 2019 to 2022 in Kenya. We comprised only recent articles written in English, identifying 50 records. We excluded 10 articles after reading title and abstract. At the end of the assessment we included in our review the 40 full-text articles. Results: The normal history of HIV infection has been intensely modified by the introduction of HAART, but HIV-infected women still have a higher risk of developing HPV-related diseases, including cervical cancer. Conclusion: Further studies are needed to obtain data about interactions between HAART and HPV-related lesions. Lastly, psychological support for cervical cancer survivors and management of late effects are needed. VL - 10 IS - 4 ER -
Information
Email: